Emcure Pharmaceuticals Ltd Financials
Company Logo

Emcure Pharmaceuticals Ltd Financial Statement

Emcure Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue1300.58
Operating Expense1033.55
Net Profit139.56
Net Profit Margin10.73
Earning Per Share7.37
EBIDTA284.13
Effective Tax Rate23.81

Emcure Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual3,497.66
Operating Expenses Annual3,055.76
Operating Profit Annual570.84
Interest Annual166.09
Depreciation189.26
Net Profit Annual160.83
Tax Annual39.08

Emcure Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning-213.05
Cash Flow from Operations584.97
Cash Flow from Investing-173.08
Cash Flow from Financing-287.75
Cash Flow at the End-88.91

Emcure Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)16.32
PBIT Margin (%)10.46
PBT Margin (%)10.40
Net PROFIT Margin (%)4.60
Return On Networth / Equity (%)8.52
Return On Networth /Employed (%)10.08
Return On Assets (%)4.41
Total Debt / Equity (X)0.89
Asset Turnover Ratio (%)0.96

Emcure Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual1,718.24
Total Current Assets Annual2,123.43
Non Current Assets Annual2,633.50
Total Shareholders Funds Annual1,935.10
Total Assets Annual4,756.93

Emcure Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

9.97

Reported

9.97

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.12%

Jun 2024

EPS beaten by -0.58%

FAQS on Emcure Pharmaceuticals Ltd Financials

As of Jul 1, 2025, Emcure Pharmaceuticals Ltd has a market capitalization of 20,327.77 Cr. Value Research classifies it as a Large-Cap company.

Yes, Emcure Pharmaceuticals Ltd is with a debt-to-equity ratio of 0.28.

In FY 2024 , Emcure Pharmaceuticals Ltd recorded a total revenue of approximately 4,381.92 Cr marking a significant milestone in the company's financial performance.

Emcure Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.2% annually, respectively..

Emcure Pharmaceuticals Ltd's current PE ratio is 64.10.

Emcure Pharmaceuticals Ltd's ROCE averaged 11.5% from the FY ending March 2023 to 2025, with a median of 10.4%. It peaked at 13.8% in March 2025, reflecting strong capital efficiency over the period..

Emcure Pharmaceuticals Ltd's latest EBIT is Rs. 540.67 Cr, surpassing the average EBIT of Rs. 428.61 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions